The FDA released additional draft and revised draft product-specific guidances, which provide recommendations on, among other things, the design of bioequivalence studies to support ANDAs. The document is set for publication in the Feb. 9 issue of the Federal Register. The agency also released a guidance on microbiology data for antibiotics, aimed at assisting sponsors in the development, analysis and presentation of microbiology data during antibacterial drug development.